SHANGHAI, CHINA, February 22, 2021 – BioNova today announced a global strategic collaboration with Ardeagen Corporation (Ardeagen), a company focused on discovery and development of Antibody Drug Conjugates (ADCs), for the discovery, development and commercialization of up to three ADCs for the treatment of oncology/hematology malignancies.